"Calcifediol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
| Descriptor ID |
D002112
|
| MeSH Number(s) |
D04.210.500.247.222.159.478.250 D04.210.500.247.808.146.478.250 D04.210.500.812.768.196.478.250 D10.570.938.146.478.250
|
| Concept/Terms |
Calcifediol- Calcifediol
- 25-Hydroxyvitamin D 3
- 25 Hydroxyvitamin D 3
- 25-Hydroxycholecalciferol Monohydrate
- 25 Hydroxycholecalciferol Monohydrate
- Monohydrate, 25-Hydroxycholecalciferol
- 25-Hydroxyvitamin D3
- 25 Hydroxyvitamin D3
- Calcidiol
- 25-Hydroxycholecalciferol
- 25 Hydroxycholecalciferol
|
Below are MeSH descriptors whose meaning is more general than "Calcifediol".
Below are MeSH descriptors whose meaning is more specific than "Calcifediol".
This graph shows the total number of publications written about "Calcifediol" by people in this website by year, and whether "Calcifediol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Calcifediol" by people in Profiles.
-
Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results. JAMA Netw Open. 2020 09 01; 3(9):e2019722.
-
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease. Am J Nephrol. 2019; 49(4):284-293.
-
Use of Extended-Release Calcifediol to Treat Secondary Hyperparathyroidism in Stages 3 and 4 Chronic Kidney Disease. Am J Nephrol. 2016; 44(4):316-325.
-
Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol. 2014; 40(6):535-45.
-
Assessment of the effect of esterified propoxylated glycerol (EPG) on the status of fat-soluble vitamins and select water-soluble nutrients following dietary administration to humans for 8 weeks. Regul Toxicol Pharmacol. 2014 Dec; 70 Suppl 2:S143-57.
-
Effect of physical activity and sun exposure on vitamin D status of Saudi children and adolescents. BMC Pediatr. 2012 Jul 03; 12:92.
-
Vitamin D is associated with atheroprotective high-density lipoprotein profile in postmenopausal women. J Clin Lipidol. 2010 Mar-Apr; 4(2):113-9.
-
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007 Jan; 71(1):31-8.
-
Bone disease after kidney transplantation. Semin Nephrol. 2004 Jan; 24(1):82-90.
-
Olestra's effect on vitamins D and E in humans can be offset by increasing dietary levels of these vitamins. J Nutr. 1997 08; 127(8 Suppl):1666S-1685S.